MedTrace Logo

Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

NCT04769297 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-02-24

No results posted yet for this study

Summary

A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.

Conditions

  • Acute Stress Disorder

Interventions

DRUG

Sublingual Micro-Dose Ketamine

daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic

Sponsors & Collaborators

  • Enovex Pharmacy

    collaborator UNKNOWN

  • Limbic Medical

    lead OTHER

Principal Investigators

  • Andre Atoian, MD · Limbic Medical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2021-04-30
Completion
2021-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769297 on ClinicalTrials.gov